within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB02_Imiglucerase;

model Imiglucerase
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 7.816666666666667e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 7.000000000000001e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00022,
    k12 = 4.55e-05,
    k21 = 4.55e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Imiglucerase</td></tr><tr><td>ATC code:</td><td>A16AB02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.07</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.7</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Imiglucerase is a recombinant enzyme replacement therapy used for the treatment of Gaucher disease type 1, a rare genetic lysosomal storage disorder. It is a modified form of the human enzyme β-glucocerebrosidase, and it helps reduce the accumulation of glucocerebroside in macrophages. Imiglucerase is approved and widely used as a standard care for Gaucher disease type 1.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with type 1 Gaucher disease following intravenous infusion. Data represent average PK values from published studies.</p><h4>References</h4><ol><li><p>Berger, J, et al., &amp; Berger, MG (2019). Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. <i>Clinical pharmacokinetics</i> 58(4) 469–482. DOI:<a href=\"https://doi.org/10.1007/s40262-018-0708-8\">10.1007/s40262-018-0708-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30128966/\">https://pubmed.ncbi.nlm.nih.gov/30128966</a></p></li><li><p>Morris, JL (2012). Velaglucerase alfa for the management of type 1 Gaucher disease. <i>Clinical therapeutics</i> 34(2) 259–271. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2011.12.017\">10.1016/j.clinthera.2011.12.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22264444/\">https://pubmed.ncbi.nlm.nih.gov/22264444</a></p></li><li><p>Sekijima, Y, et al., &amp; Fukushima, Y (2010). Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. <i>Clinical therapeutics</i> 32(12) 2048–2052. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2010.11.008\">10.1016/j.clinthera.2010.11.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21118740/\">https://pubmed.ncbi.nlm.nih.gov/21118740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A16AB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Imiglucerase;
